CAMBRIDGE, Mass. November 6, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...
– $150M transaction supporting early and clinical-stage pipeline development in OSA and related sleep disorders to find oral pharmacologic solutions for people who cannot use or tolerate current therapies CAMBRIDGE, Mass., October 31, 2023 – Apnimed, Inc., a...
— $150M transaction supporting early and clinical-stage pipeline development in OSA and related sleep disorders to find oral pharmacologic solutions for people who cannot use or tolerate current therapies CAMBRIDGE, Mass. October 31, 2023 – Apnimed, Inc., a...
CAMBRIDGE, Mass. October 10, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...
— Phase 3 Clinical Trials for AD109 Currently Enrolling Patients in the U.S. CAMBRIDGE, Mass., October 10, 2023 — Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
CAMBRIDGE, Mass. October 2, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, today announced the appointment of Paul Fonteyne, MS,...
